SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: contrarian who wrote (1410)1/6/1998 6:36:00 PM
From: Pseudo Biologist   of 1762
 
Contrarian, as long as one sticks to the labeling, I'd say the chances are close to 100%. Otherwise, one would have to ask a few oncologists directly to come up with decent estimates. The upcoming FDA reforms make off-label use easier, but I am not sure how the people who pay for the treatments are going along with this. The take home message for me was that the oncology community is enthusiastic about Rituxan, and that is a good start, I would say.

PB
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News